Ables, Iannone, Moore & Associates, Inc. Amgen Inc Transaction History
Ables, Iannone, Moore & Associates, Inc.
- $147 Billion
- Q1 2025
A detailed history of Ables, Iannone, Moore & Associates, Inc. transactions in Amgen Inc stock. As of the latest transaction made, Ables, Iannone, Moore & Associates, Inc. holds 3,360 shares of AMGN stock, worth $941,001. This represents 0.71% of its overall portfolio holdings.
Number of Shares
3,360
Previous 3,365
0.15%
Holding current value
$941,001
Previous $877 Million
19.36%
% of portfolio
0.71%
Previous 0.54%
Shares
4 transactions
Others Institutions Holding AMGN
# of Institutions
3,253Shares Held
423MCall Options Held
7.06MPut Options Held
6.41M-
Vanguard Group Inc Valley Forge, PA52.7MShares$14.8 Billion0.25% of portfolio
-
Black Rock Inc. New York, NY46MShares$12.9 Billion0.33% of portfolio
-
State Street Corp Boston, MA29.4MShares$8.24 Billion0.31% of portfolio
-
Morgan Stanley New York, NY14.6MShares$4.08 Billion0.27% of portfolio
-
Charles Schwab Investment Management Inc San Francisco, CA13.2MShares$3.7 Billion0.65% of portfolio
About AMGEN INC
- Ticker AMGN
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—General
- Shares Outstandng 534,931,008
- Market Cap $150B
- Description
- Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces th...